CXCL12-CXCR4趋化因子轴与卵巢上皮性癌关系的实验研究  

Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer

作　　者：郭清[1] 吴小华 吕英璞[1] 杨波[2] 徐峰[1] 张少静[1] 

机构地区：[1]石家庄市第一医院妇产科,050011 [2]白求恩国际和平医院妇产科

出　　处：《中华医学杂志》2013年第21期1677-1680,共4页National Medical Journal of China

摘　　要：目的探讨CXCL12-CXCR4趋化因子轴与卵巢上皮癌发病、转移的关系。方法将转染质粒SKOV3／CXCR4、转染载体SKOV3／neg及未转染的SKOV3三种卵巢癌细胞进行体外培养；采用四甲基偶氮唑蓝（MTT）比色法进行增殖实验，研究不同浓度的CXCL12、CXCR4抗体和CXCR4拮抗剂AMD3100对3种细胞增殖、迁移、侵袭的影响。观察各组裸鼠自然死亡后腹腔成瘤数、体积和存活期的变化。结果（1）CXCL12单独作用可促进SKOV3／CXCR4细胞的增殖、迁移、侵袭，且高浓度作用强（P〈0．05）；（2）CXCL12致瘤作用可被CXCR4中和抗体或CXCR4拮抗剂AMD3100抑制（P〈0．05）；（3）3组裸鼠生存时问、腹腔移植瘤的个数和重量相比差异有统计学意义（P〈0．05），CXCL12浓度越高受试裸鼠腹腔移植瘤个数越多，重量越大生存时间越短。结论CXCL12-CXCR4趋化因子轴与卵巢上皮癌发生及转移密切相关，CXCL12-CXCR4趋化因子轴可能是卵巢癌发生的一个重要原因，抗CXCL12-CXCR4治疗卵巢上皮癌可能有效。Objective To explore the relationship between chemokine axis CXCL12-CXCR4 and the pathogenesy and severity of epithelial ovarian cancer. Methods SKOV3 transfeeted with plasmid, SKOV3 transfected with vector and SKOV3 were cultured in vitro. Methyl thiazolyl tetrazolium （MTT） was used to analyze the effects of different concentrations of CXCL12 on the proliferation, migration and invasion of three cell lines and examine the inhibition of neutralizing CXCR4 antibody or antagonist AMD3100. And the load and weight of acquired tumor were determined at different concentrations of CXCL12. Results CXCL12 could promote the proliferation, migration and invasion of SKOV3/CXCR4 cells in a dose- dependent fashion （ P 〈 0.05 ）. The effect on CXCL12 tumorigenesis could be inhibited by neutralizing CXCR4 antibody or antagonist AMD3100 （P 〈 0.05 ）. Significant differences existed in the mean survival time, load and weight of metastatic tumors among the three nude mice. Conclusion A close correlation exists between hemokine axis CXCL12-CXCR4 and the pathogenesis, metastasis of epithelial ovarian cancer. The above axis may be an important pathogenic factor of epithelial ovarian cancer. And the antibody of CXCL12-CXCR4 is probably effective in its management.

关 键 词：趋化因子CXCL12 受体CXCR4 卵巢肿瘤 腹腔 肿瘤转移 

分 类 号：R737[医药卫生—肿瘤]